Format

Send to

Choose Destination
Eur Heart J. 2015 Dec 7;36(46):3258-64. doi: 10.1093/eurheartj/ehv476. Epub 2015 Sep 29.

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.

Author information

1
Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA emily.obrien@duke.edu.
2
Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
3
Boston University School of Medicine, Boston, MA, USA.
4
Mayo Clinic, Rochester, MN, USA.
5
Hofstra North Shore/LIJ School of Medicine, Hempstead, NY, USA.
6
Jefferson Medical College, Philadelphia, PA, USA.
7
Stanford University School of Medicine, Stanford, CA, USA.
8
Janssen Scientific Affairs, Raritan, NJ, USA.
9
UCLA Division of Cardiology, Los Angeles, CA, USA.

Abstract

BACKGROUND:

Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations.

OBJECTIVES:

We sought to develop and validate a novel bleeding risk score using routinely available clinical information to predict major bleeding in a large, community-based AF population.

METHODS:

We analysed data from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), a prospective registry that enrolled incident and prevalent AF patients at 176 US sites. Using Cox proportional hazards regression, we identified factors independently associated with major bleeding among patients taking oral anticoagulation (OAC) over a median follow-up of 2 years (interquartile range = 1.6-2.5). We also created a numerical bedside risk score that included the five most predictive risk factors weighted according to their strength of association with major bleeding. The predictive performance of the full model, the simple five-item score, and two existing risk scores (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly, HAS-BLED, and anticoagulation and risk factors in atrial fibrillation, ATRIA) were then assessed in both the ORBIT-AF cohort and a separate clinical trial population, Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET-AF).

RESULTS:

Among 7411 ORBIT-AF patients taking OAC, the rate of major bleeding was 4.0/100 person-years. The full continuous model (12 variables) and five-factor ORBIT risk score (older age [75+ years], reduced haemoglobin/haematocrit/history of anaemia, bleeding history, insufficient kidney function, and treatment with antiplatelet) both had good ability to identify those who bled vs. not (C-index 0.69 and 0.67, respectively). These scores both had similar discrimination, but markedly better calibration when compared with the HAS-BLED and ATRIA scores in an external validation population from the ROCKET-AF trial.

CONCLUSIONS:

The five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support clinical decision making.

KEYWORDS:

Anticoagulants; Atrial fibrillation; Major bleeding; Risk prediction

PMID:
26424865
PMCID:
PMC4670965
DOI:
10.1093/eurheartj/ehv476
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center